Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Neurosense Therapeutics Ltd (NRSN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NRSN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.75
1 Year Target Price $10.75
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.44% | Avg. Invested days 27 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.58M USD | Price to earnings Ratio - | 1Y Target Price 10.75 |
Price to earnings Ratio - | 1Y Target Price 10.75 | ||
Volume (30-day avg) 3 | Beta 1.6 | 52 Weeks Range 0.51 - 2.60 | Updated Date 06/29/2025 |
52 Weeks Range 0.51 - 2.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -159.5% | Return on Equity (TTM) -2478.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42273471 | Price to Sales(TTM) - |
Enterprise Value 42273471 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.16 | Shares Outstanding 23988700 | Shares Floating 11925007 |
Shares Outstanding 23988700 | Shares Floating 11925007 | ||
Percent Insiders 30.98 | Percent Institutions 0.81 |
Analyst Ratings
Rating 2 | Target Price 10.75 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Neurosense Therapeutics Ltd
Company Overview
History and Background
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. Founded in 2016, the company's primary focus has been on amyotrophic lateral sclerosis (ALS). Key milestones include preclinical and clinical trial advancements of its lead compounds.
Core Business Areas
- Drug Development: Focuses on developing and commercializing novel therapeutics for neurodegenerative diseases, including ALS.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Development: Engages in ongoing research to identify and develop new therapeutic targets.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and biotechnology. The organizational structure is typical of a small biotechnology company, with a focus on research, clinical development, and business development.
Top Products and Market Share
Key Offerings
- PrimeC: PrimeC is Neurosense's leading drug candidate, a combination therapy intended for ALS treatment. It is currently undergoing clinical trials. Market share is currently 0% as the product is not yet approved. Competitors include existing ALS treatments from Mitsubishi Tanabe Pharma (Radicava) and Amylyx Pharmaceuticals (Relyvrio).
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is large and growing, driven by an aging population and increasing prevalence of diseases like ALS and Alzheimer's. The market is highly competitive with significant unmet needs.
Positioning
Neurosense Therapeutics is positioned as a company focused on addressing unmet needs in ALS treatment. Its competitive advantage lies in its novel therapeutic approach with PrimeC.
Total Addressable Market (TAM)
The global ALS market is expected to reach several billion USD. Neurosense is positioned to capture a portion of this TAM with a successful product launch, pending regulatory approval and clinical trial outcomes.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach for ALS
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Single lead product
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Funding risks
Competitors and Market Share
Key Competitors
- MTPC.JP
- AMLY
Competitive Landscape
Neurosense competes with established pharmaceutical companies and other biotechnology firms developing treatments for ALS. Its competitive advantage lies in its novel therapeutic approach, but it faces challenges due to its limited resources and dependence on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and successful fundraising.
Future Projections: Future growth projections are dependent on the success of PrimeC in clinical trials and subsequent regulatory approval. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing Phase IIb clinical trials for PrimeC and exploration of potential partnerships.
Summary
Neurosense Therapeutics is a high-risk, high-reward clinical-stage company focused on ALS. Positive clinical trial results for PrimeC could significantly increase the company's value. However, the company is highly dependent on the success of its lead product and faces significant regulatory and funding risks. Its early stage revenue is a factor to consider.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment in biotechnology companies is highly speculative and involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurosense Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.neurosense-tx.com |
Full time employees 17 | Website https://www.neurosense-tx.com | ||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.